Display options
Cite
Wan KS, Liu YC, Huang CS, et al. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: A randomized clinical trial. Allergy Rhinol (Providence). 2016;7(3):131-134doi: 10.2500/ar.2016.7.0168.
Wan, K. S., Liu, Y. C., Huang, C. S., & Su, Y. M. (2016). Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: A randomized clinical trial. Allergy & rhinology (Providence, R.I.), 7(3), 131-134. https://doi.org/10.2500/ar.2016.7.0168
Wan, Kong-Sang, et al. "Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: A randomized clinical trial." Allergy & rhinology (Providence, R.I.) vol. 7,3 (2016): 131-134. doi: https://doi.org/10.2500/ar.2016.7.0168
Wan KS, Liu YC, Huang CS, Su YM. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: A randomized clinical trial. Allergy Rhinol (Providence). 2016 Jan 01;7(3):131-134. doi: 10.2500/ar.2016.7.0168. PMID: 28107143; PMCID: PMC5244267.
Copy Download .nbib Format: NLM
Share it on

Allergy Rhinol (Providence). 2016 Jan 01;7(3):131-134. doi: 10.2500/ar.2016.7.0168.

Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: A randomized clinical trial.

Allergy & rhinology (Providence, R.I.)

Kong-Sang Wan, Yu-Cheng Liu, Che-Sheng Huang, Yu-Mao Su

PMID: 28107143 PMCID: PMC5244267 DOI: 10.2500/ar.2016.7.0168

Abstract

BACKGROUND: Macrolides exert anti-inflammatory and immunomodulatory effects beyond their purely antibacterial action, as demonstrated by several bronchial inflammatory disorders, including asthma.

METHODS: Fifty-eight children with newly diagnosed mild persistent asthma were selected by using the Global Initiative for Asthma guidelines and were randomly divided into the study (group I) (n = 36) and control (group II) (n = 22) groups. Mycoplasma pneumonia-specific immunoglobulin G and -specific immunoglobulin M antibody levels of each participant were measured by enzyme-linked immunosorbent assay. Clarithromycin 5 mg/kg daily and placebo were given to groups I and II, respectively, for 4 weeks. All of the children had maintenance inhaled corticosteroid (fluticasone propionate, one puff twice [50 μg/puff] daily). Forced expiratory volume in 1 second, forced expiratory flow at 25-75% of the pulmonary volume, exhaled nitric oxide value, total IgE level, absolute eosinophil count, and eosinophilic cation protein value were measured at baseline and at the end of the treatment.

RESULTS: There are significantly increased forced expiratory volume in 1 second and forced expiratory flow at 25-75% of the pulmonary volume levels and decreased exhaled nitric oxide values after the 4-week clarithromycin treatment. The study group also had a decreased peripheral blood absolute eosinophil count and eosinophilic cation protein level, but not for the total IgE level, after the treatment.

CONCLUSION: Four weeks of sub-antimicrobial doses of clarithromycin may improve pulmonary function and decrease eosinophilic inflammation in children with asthma.

Conflict of interest statement

The authors have no conflicts of interest to declare pertaining to this article

References

  1. Pharmacol Ther. 2008 Mar;117(3):393-405 - PubMed
  2. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004875 - PubMed
  3. Curr Allergy Asthma Rep. 2004 Mar;4(2):132-8 - PubMed
  4. Ann Allergy Asthma Immunol. 2001 Dec;87(6):501-5 - PubMed
  5. Curr Opin Pharmacol. 2012 Jun;12(3):293-9 - PubMed
  6. Clin Microbiol Rev. 2010 Jul;23(3):590-615 - PubMed
  7. Ther Adv Infect Dis. 2013 Aug;1(4):121-38 - PubMed
  8. Chest. 2007 Dec;132(6):1962-6 - PubMed
  9. Respiration. 2011;81(1):75-87 - PubMed
  10. Respiration. 2011;81(1):67-74 - PubMed
  11. Pulm Pharmacol Ther. 2015 Apr;31:99-108 - PubMed
  12. J Thorac Dis. 2013 Oct;5(5):613-7 - PubMed
  13. Eur Respir J. 2013 Jul;42(1):239-51 - PubMed
  14. Chest. 2010 Nov;138(5):1202-12 - PubMed
  15. Clin Exp Allergy. 2012 Sep;42(9):1302-12 - PubMed
  16. Immunol Allergy Clin North Am. 2010 Nov;30(4):575-85, vii-viii - PubMed
  17. Eur J Clin Pharmacol. 2012 May;68(5):479-503 - PubMed
  18. Am J Respir Crit Care Med. 2015 Sep 1;192(5):551-8 - PubMed
  19. Curr Allergy Asthma Rep. 2010 Jan;10(1):67-73 - PubMed
  20. Rev Mal Respir. 2010 Oct;27(8):890-7 - PubMed
  21. Allergol Immunopathol (Madr). 2010 Mar-Apr;38(2):92-8 - PubMed
  22. Respir Med. 2013 Jun;107(6):800-15 - PubMed
  23. Pediatr Infect Dis J. 2000 Aug;19(8):706-10 - PubMed
  24. Allergy. 2013 Aug;68(8):1040-9 - PubMed
  25. J Immunol. 1999 Sep 1;163(5):2909-15 - PubMed

Publication Types